BR112013031117A8 - Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. - Google Patents

Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.

Info

Publication number
BR112013031117A8
BR112013031117A8 BR112013031117A BR112013031117A BR112013031117A8 BR 112013031117 A8 BR112013031117 A8 BR 112013031117A8 BR 112013031117 A BR112013031117 A BR 112013031117A BR 112013031117 A BR112013031117 A BR 112013031117A BR 112013031117 A8 BR112013031117 A8 BR 112013031117A8
Authority
BR
Brazil
Prior art keywords
inositol
scyllo
myo
brain
individual
Prior art date
Application number
BR112013031117A
Other languages
English (en)
Other versions
BR112013031117A2 (pt
Inventor
Hernandez Ramon
Abushakra Susan
Crans Gerald
Cedar-Baum Jesse
Original Assignee
Elan Pharm Inc
Elan Pharmaceuticals Llc
Transition Therapeutics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Elan Pharmaceuticals Llc, Transition Therapeutics Ireland Ltd filed Critical Elan Pharm Inc
Publication of BR112013031117A2 publication Critical patent/BR112013031117A2/pt
Publication of BR112013031117A8 publication Critical patent/BR112013031117A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SCILO-INOSITOL PARA O TRATAMENTO DE TRANSTORNOS COMPORTAMENTAIS E PSIQUIÁTRICOS. Descobriu-se inesperadamente que a administração de scilo-inositol a um paciente regula para baixo (isto é, diminui) o nível de mio-inositol no cérebro de tais pacientes, além de atrasar o surgimento e diminuir o grau dos sintomas neuropsiquiátricos (SNP). Consequentemente, em um aspecto da invenção, é proporcionado um método para reduzir o nível de mio-inositol no cérebro de um indivíduo, o qual consiste em administrar uma quantidade eficaz de scilo-insolitol ao indivíduo. Em alguns aspectos, a invenção proporciona scilo-inositol ou uma composição farmacêutica contendo scilo-inositol fpara ser utilizada na redução do nível de, ou na regulação para baixo do mio-inositol no cérebro de um indivíduo, ou ainda na preparação de um medicamento para reduzi o nível de, ou regular para baixo o mio-inositol no cérebro de um indivíduo.
BR112013031117A 2011-06-03 2012-06-04 Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. BR112013031117A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161520031P 2011-06-03 2011-06-03
US201161541333P 2011-09-30 2011-09-30
US201261618680P 2012-03-31 2012-03-31
PCT/US2012/040789 WO2012173808A1 (en) 2011-06-03 2012-06-04 Scyllo-inositol for the treatment of behavioral and psychiatric disorders

Publications (2)

Publication Number Publication Date
BR112013031117A2 BR112013031117A2 (pt) 2018-06-19
BR112013031117A8 true BR112013031117A8 (pt) 2018-08-14

Family

ID=46298680

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031117A BR112013031117A8 (pt) 2011-06-03 2012-06-04 Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.

Country Status (11)

Country Link
US (1) US20140243422A1 (pt)
EP (1) EP2714050A1 (pt)
JP (1) JP2014515408A (pt)
KR (1) KR20140041670A (pt)
CN (1) CN103906520A (pt)
AU (1) AU2012271068A1 (pt)
BR (1) BR112013031117A8 (pt)
CA (1) CA2837926A1 (pt)
IL (1) IL229658A0 (pt)
RU (1) RU2013154699A (pt)
WO (1) WO2012173808A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2014110234A1 (en) * 2013-01-09 2014-07-17 Elan Pharmaceuticals, Llc Methods of treating developmental and personality disorders
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
WO2017004226A1 (en) * 2015-06-30 2017-01-05 Jds Therepeutics, Llc Arginine silicate inositol for improving cognitive function
WO2017029353A1 (en) * 2015-08-20 2017-02-23 Transition Therapeutics Ireland Limited Treatment of behaviors in dementia patients
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
EP3506895A4 (en) 2016-09-01 2020-04-15 JDS Therapeutics, LLC MAGNESIUM BIOTINATE COMPOSITIONS AND METHODS OF USE
KR20210110572A (ko) 2018-11-02 2021-09-08 뉴트리션 21, 엘엘씨 비디오 게이머의 인지 기능 개선을 위한 이노시톨 안정화 아르기닌 실리케이트 복합체 및 이노시톨을 함유하는 조성물
CA3162952A1 (en) * 2019-12-02 2021-06-10 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
WO2024054415A1 (en) * 2022-09-07 2024-03-14 Eirgen Pharma, Ltd. A combination of scyllo-inositol and flavones
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
KR101314079B1 (ko) 2003-10-14 2013-10-04 혹꼬우 가가꾸 고오교오 가부시끼가이샤 실로-이노시톨의 제조방법
WO2007101353A1 (en) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
CN101505741A (zh) * 2006-03-09 2009-08-12 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂
AU2011215616A1 (en) 2010-02-15 2012-09-06 Transition Therapeutics Ireland Limited Process for the preparation of scyllo-Inositol
US20150306043A1 (en) * 2012-09-28 2015-10-29 Transition Therapeutics Ireland Limited Combination treatments for bipolar disorders

Also Published As

Publication number Publication date
RU2013154699A (ru) 2015-07-20
CA2837926A1 (en) 2012-12-20
EP2714050A1 (en) 2014-04-09
WO2012173808A1 (en) 2012-12-20
CN103906520A (zh) 2014-07-02
US20140243422A1 (en) 2014-08-28
BR112013031117A2 (pt) 2018-06-19
AU2012271068A1 (en) 2013-12-19
JP2014515408A (ja) 2014-06-30
IL229658A0 (en) 2014-01-30
KR20140041670A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
BR112012006010A2 (pt) composto de glicina
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
Chen et al. Fisetin protects against intracerebral hemorrhage-induced neuroinflammation in aged mice
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
PH12015502655A1 (en) Method
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112014009141A8 (pt) regime de dosagem para um modulador ou agonista do receptor s1p

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ELAN PHARMACEUTICALS, LLC (US)

B25A Requested transfer of rights approved

Owner name: TRANSITION THERAPEUTICS IRELAND LIMITED (CA)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.